OBJECTIVE: To evaluate the treatment indications, effectiveness and adverse events of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes mellitus using data from a registry at METHODS: The registry included patients with type 1 diabetes who had converted from multiple daily injection (MDI) to CSII. Patients with complete data sets covering a period of ≥ 3 years were included in the study (n = 184). Complications, glycaemic control and insulin dose during CSII were compared with data obtained during MDI. RESULTS: CSII resulted in significant reductions in glycosyated haemoglobin level and total daily insulin dose. The mean number of severe hypoglycaemic episodes during CSII was 0.17 per patient per year. CONCLUSIONS: Treatment of adults with type 1 diabetes mellitus by CSII can improve glycaemic control and reduce insulin requirements compared with MDI, however patient selection, education and continuous care are important parts of this therapy.
Introduction
Treatment goals in type 1 diabetes mellitus include achieving near-normal glucose levels, minimizing the risk of hypoglycaemia and preventing or delaying long-term microvascular and macrovascular complications. 1, 2 Continuous subcutaneous insulin infusion (CSII) is an intensified insulin therapy that can assist in the attainment of these goals. Since its introduction, the effectiveness of CSII in maintaining good glycaemic control has been confirmed in the Diabetes Control and Complications Trial and various other studies. 2 -6 It is well established that CSII is better at mimicking the physiological situation and it has also been shown to be more effective than multiple daily injections (MDI) in a A Janez Continuous subcutaneous insulin infusion in type 1 diabetes number of clinical studies 7 -14 and metaanalyses. 15 -17 CSII can reduce glycosylated haemoglobin (HbA 1c ) and the frequency of severe hypoglycaemia, particularly in conjunction with the use of new insulin analogues and improvements in pump technology. 13,14,18 -22 There are only limited data available, however, on the effectiveness and safety of CSII in adults in everyday clinical practice, who may differ substantially from the carefully selected and closely monitored populations included in clinical trials. For this reason, the University Medical Centre Ljubljana (Ljubljana, Slovenia), established a registry to collect data on all patients treated with CSII in everyday clinical practice. The aim of the present study was to use this registry to evaluate the effectiveness and safety of CSII under real-life conditions in patients with type I diabetes. Glycaemic control (assessed via HbA 1c ) during CSII was compared with that during MDI treatment in the year before CSII treatment commenced. Known CSIIassociated adverse events, such as severe hypoglycaemia, ketoacidosis and local skin infections, were also recorded and evaluated.
Patients and methods

STUDY POPULATION
All adult patients with type 1 diabetes who had converted from multiple daily injection (MDI) to CSII and were being treated by the Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia, between January 2000 and January 2011 were eligible for inclusion in the study. Only those patients and had complete data sets covering a period of ≥ 3 years were actually enrolled.
Ethical approval for the registry was obtained from the Ethics Committee at the University Medical Centre Ljubljana and patients provided verbal informed consent for their data to be included in the CSII registry and in the present study.
DATA SETS
The clinical data included in the CSII registry were collected from patients at least once a year using the OpenClinica ® electronic data capture system (OpenClinica, Waltham, MA, USA) or by questionnaire as described by Clarke et al. 23 The registry included the following data: gender; date of birth; duration of diabetes; date of onset of CSII; indication for CSII (poor glycaemic control, severe hypoglycaemia, diabetic neuropathy, other late diabetic complications, preconception care, kidney transplantation, dawn phenomenon, brittle diabetes, patient's wish); smoking status; chronic microvascular and macrovascular diabetic complications; body weight; height; body mass index (BMI); the final three HbA 1c values from the year before CSII began; the type and dosage of insulin used in MDI; the type and dosage of insulin used in CSII; and the type of insulin pump used. The following were monitored and recorded every 3 months: body weight; height; BMI; HbA 1c in blood; insulin dosage (total, prandial and basal insulin); and the incidence of CSII-related complications (such as severe hypoglycaemia, ketoacidosis, local skin infections). The automated highperformance liquid chromatography Variant II™ haemoglobin testing system (Bio-Rad, Hercules, CA, USA) was used to determine the level of HbA 1c in blood.
STATISTICAL ANALYSES
The mean ± SD of the data were calculated. All statistical analyses were performed using SPSS ® statistical package version 12.0F (SPSS Inc., Chicago, IL, USA), for Windows ® . Student's t-test was used for betweentreatment comparisons; a P-value < 0.05 was considered statistically significant.
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Results
A total of 184 adult patients with type 1 diabetes and complete data sets covering a period of ≥ 3 years were included in the study (55 males/129 females). Their demographic and clinical characteristics are summarized in Table 1 . The numbers of patients using the various types of pump and types of insulin in CSII are shown in Table 2 .
A significant decrease in levels of HbA 1c at 1, 2 and 3 years after changing from MDI insulin therapy to SCII was seen ( Table 3 ; P < 0.001 for all comparisons). Similarly, the mean total daily insulin doses in each of the 
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3-years after changing from MDI insulin therapy to SCII were also significantly lower ( Table 3 ; P < 0.001 for all comparisons). The mean ± SD basal insulin dose on CSII was 22.0 ± 4.2 IU/day, equivalent to 0.5 ± 0.2 IU/kg per day, and the prandial insulin dose during CSII was 17.0 ± 6.2 IU/day.
In terms of the incidence of CSII-related complications, the mean number of severe hypoglycaemic episodes during CSII was 0.17 per patient per year and these occurred in 11 patients during the 3-year follow-up period (three of these patients each had two severe hypoglycaemic episodes). There were seven episodes of ketoacidosis in five patients (two of these patients each experienced two episodes) and three patients reported severe skin infections.
Discussion
The CSII registry of patients with type 1 diabetes at the University Medical Centre Ljubljana objectively and continually monitors treatment using insulin pumps. It was primarily established as a tool for evaluating the effectiveness of glycaemic control in CSII treatment. Insulin pump therapy became available in Slovenia in the about the last decade and is now used nationwide by > 1000 adults with type 1 diabetes. The current study evaluated the treatment indications, adverse events and effectiveness of CSII in adults with type 1 diabetes. In order to increase the quality of the data, only those patients with continuous data covering a period of ≥ 3 years were included.
A significant clinical effect of switching from MDI to CSII was demonstrated in the present study and these results are particularly relevant to everyday clinical practice. Randomized controlled trials do not reflect daily clinical practice as the participants are highly selected. The use of CSII registry data, therefore, allows systematic and objective analysis of routine clinical care and relevant outcomes. Glycaemic control (evaluated via HbA 1c levels) was significantly improved by CSII throughout the 3-year duration of the study. Similar improvements were found in three meta-analyses and one observational study. 10,15 -17 The meta-analysis by Pickup et al. 15 performed in 2002 showed a standardized mean decrease in HbA 1c of 0.44 and a standardized mean decrease in insulin dose of 0.58 (equivalent to an effect size of 7.58 IU/day) in patients treated with CSII compared with MDI. The findings of the current study are clinically relevant because it included an unselected patient group that had been cared for by the same clinical team during both MDI and CSII. Baseline HbA 1c levels in the current study were higher than 
3: Glycosylated haemoglobin (HbA 1c ) levels and total daily insulin dose over a period of 3 years in patients with type 1 diabetes after changing from multiple daily injection (MDI) insulin therapy to continuous subcutaneous insulin infusion (CSII) (n = 184)
CSII
Parameters
MDI After 1 year After 2 years After 3 years
HbA 1c , % 7.6 ± 0.9 6.9 ± 0.9*** 6.9 ± 0.6*** 7.0 ± 0.6*** Total insulin, IU/day 48.9 ± 16. • Received for publication 25 February 2012 • Accepted subject to revision 1 March 2012 • Revised accepted 23 July 2012 Copyright © 2012 Field House Publishing LLP the treatment goal of < 6.5% recommended by the American Diabetes Association for patients with type 1 diabetes 24 but this was consistent with insufficient glycaemic control being the major indication for CSII in this and other studies. 8, 9, 12, 13 Other common indications for CSII in the present study were trying to conceive/pregnancy and unawareness of hypoglycaemia.
Data from insulin pump registries are limited. A French regional registry included 424 patients but they were a mixture of both types 1 and 2. 25 A study in Denmark of 142 type 1 diabetes patients from 73 centres found that, despite having a positive effect on metabolic control, CSII was used infrequently (only approximately 0.5% of patients) and there were significant differences in uptake between individual centres. 26 A retrospective analysis of 167 patients with type 1 diabetes treated with CSII in three hospitals in Finland found major regional differences in the use of insulin pumps, in spite of improvement in glycaemic control. 10 Finally, data from a national register of CSII-treated patients in the Czech Republic revealed a significant reduction in HbA 1c levels after treatment. 27 The present study of the long-term (3year) use of CSII at the University Medical Centre Ljubljana demonstrated that CSII achieved better glycaemic control than MDI. CSII allows a more flexible lifestyle and has few adverse effects in most patients, but it is important to balance these advantages against the higher costs and technical demands compared with MDI and, in the case of technical failure, the higher risk of diabetic ketoacidosis. 28 Patient selection, education and continuous care are important in order to minimize the risk of metabolic emergencies during CSII.
In conclusion, the CSII registry of the University Medical Centre Ljubljana provided valuable information that demonstrated the effectiveness of CSII in an everyday clinical setting, whilst also highlighting the risk of severe hypoglycaemia and ketoacidosis in a small proportion of patients. Based on our clinical experience, we conclude that CSII is an effective treatment for selected adult patients with type 1 diabetes, however patient selection, education and continuous care are important to minimize the risk of metabolic emergencies.
